Isis Biopolymer (“Isis”) is engaged in the development of intelligent transdermal patches based on the IsisIQ™ platform. The Company is applying advancements in miniaturization and electronics packaging to provide active transdermal infusion technology for the next generation of drug delivery. Active transdermal infusion is a method whereby electro-stimulation is used to drive molecules of interest across the skin non-invasively in a controlled and repeatable manner. Unlike passive transdermal technologies, which rely on nature to produce results (e.g. osmosis), and which are slow and only allow small amounts of drugs to cross the skin, or dual-electrode iontophoresis technologies, which form a circuit to force the molecules into the skin, often resulting in irritation and burning, the Isis patented single electrode technology pushes molecules into the skin painlessly in high enough quantities to open up new avenues in transdermal applications.

Isis is presently applying its advanced transdermal delivery to the science of anti-aging and anti-wrinkle to speed the uptake of well-known anti-aging agents, shortening the time to see results from weeks to one hour. The Isis anti-wrinkle patch, Biobliss™, is being launched this summer.
 
The IsisIQ patch’s design and novelty are protected by Isis’ intellectual property rights, including one approved and issued patent and seven pending patent applications. Isis was founded in 2007 and is led by a veteran team with deep expertise in medical devices, materials and systems design. Isis has a fabrication, research and development facility in Providence, Rhode Island, located in the “Knowledge District.”